Zingerone activates VMAT2 during MPP(+) -induced Cell Death.
Parkinson's disease (PD) is characterized by a progressive and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and striatum. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is used to produce an animal model for PD, and it is converted to 1-methyl-4-phenylpyridine (MPP(+)) in animals. MPP(+) accumulation leads to neuronal cell death. Vesicular monoamine transporter 2 (VMAT2) regulates the accumulation of monoamine neurotransmitters into synaptic vesicles and is involved in neuroprotection against neurotoxin-induced cell death. Recently, zingerone has been reported to reduce oxidative stress and inhibit inflammation. Therefore, we examined the effect of zingerone on neuronal cell death in a PD model. In an MPP(+) and MPTP-mediated PD model, neuronal cell survival was increased by zingerone without modifying neuroinflammation or reactive oxygen species generation. Zingerone also induced ERK activation and VMAT2 expression, leading to the attenuation of MPP(+)-induced neuronal cell death. Our current results suggest that zingerone has a neuroprotective effect in a PD model.
Department of Anatomy and Neurobiology, Kyung Hee University, Seoul, Korea.
Jae-Sun
JS
Choi
Department of Anatomy and Neurobiology, Kyung Hee University, Seoul, Korea.
Woom-Yee
WY
Bae
Department of Anatomy and Neurobiology, Kyung Hee University, Seoul, Korea.
Chan
C
Park
Department of Anatomy and Neurobiology, Kyung Hee University, Seoul, Korea.
Joo-Won
JW
Jeong
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000818:Animals; D016923:Cell Death / Q000187:drug effects*; D003342:Corpus Striatum / Q000187:drug effects; D004195:Disease Models, Animal; D059290:Dopaminergic Neurons / Q000187:drug effects; D004347:Drug Interactions; D006139:Guaiacol / Q000031:analogs & derivatives* / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000494:pharmacology; D009498:Neurotoxins; D010300:Parkinson Disease / Q000188:drug therapy; D050493:Vesicular Monoamine Transport Proteins / Q000378:metabolism*
D018696:Neuroprotective Agents; D009498:Neurotoxins; D050493:Vesicular Monoamine Transport Proteins; C013738:zingerone; D006139:Guaiacol; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
ERK; MPTP/MPP+; Parkinson's disease; VMAT2; zingerone